{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:50:55Z","timestamp":1791942655281,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.ijantimicag.2012.12.012","type":"journal-article","created":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T15:36:04Z","timestamp":1364312164000},"page":"426-433","source":"Crossref","is-referenced-by-count":35,"title":["Linezolid versus vancomycin for meticillin-resistant Staphylococcus aureus infection: a meta-analysis of randomised controlled trials"],"prefix":"10.1016","volume":"41","author":[{"given":"Mao Mao","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Dong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo Tong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan Ying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 5","key":"10.1016\/j.ijantimicag.2012.12.012_bib0005","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1086\/533590","article-title":"Epidemiology of methicillin-resistant Staphylococcus aureus","volume":"46","author":"Boucher","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0010","doi-asserted-by":"crossref","first-page":"R97","DOI":"10.1186\/cc4934","article-title":"Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia","volume":"10","author":"Shorr","year":"2006","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0015","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijantimicag.2011.09.028","article-title":"New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance","volume":"39","author":"Gould","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0020","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1086\/527392","article-title":"Vancomycin-resistant Staphylococcus aureus in the United States, 2002\u20132006","volume":"46","author":"Sievert","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1128\/CMR.00042-09","article-title":"Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection and clinical implications","volume":"23","author":"Howden","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0030","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1021\/jm800038g","article-title":"Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious Gram-positive infections","volume":"51","author":"Brickner","year":"2008","journal-title":"J Med Chem"},{"issue":"Suppl. 4","key":"10.1016\/j.ijantimicag.2012.12.012_bib0035","first-page":"iv7","article-title":"Linezolid pharmacokinetics and pharmacodynamics in clinical treatment","volume":"66","author":"Dryden","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0040","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0045","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.amjsurg.2009.08.045","article-title":"Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus","volume":"199","author":"Itani","year":"2010","journal-title":"Am J Surg"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0050","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1086\/595686","article-title":"Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study","volume":"48","author":"Wilcox","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0055","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1378\/chest.08-0011","article-title":"Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus","volume":"134","author":"Wunderink","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0060","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jac\/dkm369","article-title":"Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan","volume":"60","author":"Kohno","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0065","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1128\/AAC.49.6.2260-2266.2005","article-title":"Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections","volume":"49","author":"Weigelt","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0070","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.amjsurg.2005.01.011","article-title":"Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus","volume":"189","author":"Sharpe","year":"2005","journal-title":"Am J Surg"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0075","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.amjsurg.2004.08.045","article-title":"Linezolid eradicates MRSA better than vancomycin from surgical-site infections","volume":"188","author":"Weigelt","year":"2004","journal-title":"Am J Surg"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0080","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/340353","article-title":"Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections","volume":"34","author":"Stevens","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0085","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0095","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/archinte.1996.00440060089011","article-title":"The importance of quality of primary studies in producing unbiased systematic reviews","volume":"156","author":"Khan","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0100","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1017\/S0266462300009570","article-title":"Assessing the quality of randomized controlled trials. Current issues and future directions","volume":"12","author":"Moher","year":"1996","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0105","series-title":"Methods for meta-analysis in medical research","author":"Sutton","year":"2000"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1473-3099(07)70312-2","article-title":"Linezolid versus glycopeptide or \u03b2-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials","volume":"8","author":"Falagas","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijantimicag.2009.09.013","article-title":"Linezolid versus vancomycin for the treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials","volume":"35","author":"Beibei","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0120","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1097\/CCM.0b013e3181eb3b96","article-title":"Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis","volume":"38","author":"Kalil","year":"2010","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0125","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.diagmicrobio.2009.10.011","article-title":"Linezolid surveillance program results for 2008 (LEADER Program for 2008)","volume":"65","author":"Farrell","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0130","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0149-2918(07)80085-3","volume":"29","author":"McCollum","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0135","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1742-1241.2008.01958.x","article-title":"Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model","volume":"63","author":"Bounthavong","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0140","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1258\/1355819021927674","article-title":"Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice","volume":"7","author":"Higgins","year":"2002","journal-title":"J Health Serv Res Policy"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0145","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ijantimicag.2012.12.012_bib0150","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/bmj.309.6965.1351","article-title":"Why sources of heterogeneity in meta-analysis should be investigated","volume":"309","author":"Thompson","year":"1994","journal-title":"BMJ"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857913000228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857913000228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T18:52:19Z","timestamp":1539802339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857913000228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0924857913000228"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2012.12.012","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}